Description

CJC-1295 Without DAC

Modified GHRH Analogue | Experimental Peptide Research Compound

CJC-1295 Without DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH) designed to investigate pathways involved in growth-hormone secretion. Unlike the long-acting DAC form of CJC-1295, the Without DAC variant does not contain the Drug Affinity Complex modification associated with prolonged albumin binding.

The compound is primarily investigated in peptide pharmacology, growth-hormone signaling, endocrine research, and receptor biology. Research on different CJC-1295 preparations should be distinguished carefully because their pharmacokinetic and pharmacological profiles can differ substantially.

Key Characteristics

  • Product Name: CJC-1295 Without DAC
  • Compound Type: Synthetic GHRH analogue
  • Primary Target: Growth hormone-releasing hormone receptor pathway
  • Research Areas: Growth hormone signaling, endocrine physiology, peptide pharmacology, and receptor research
  • Form: Synthetic peptide
  • Research Status: Experimental / investigational
  • Intended Use: Laboratory and analytical research

Research Profile

CJC-1295 Without DAC is designed to interact with pathways associated with GHRH receptor signaling and growth-hormone release. As a GHRH analogue, it provides a research model for investigating how modified peptide structures influence receptor interaction and downstream endocrine signaling.

The absence of the DAC modification is an important distinguishing characteristic. Researchers studying CJC-1295 should therefore avoid treating CJC-1295 Without DAC and CJC-1295 with DAC as interchangeable materials.

Research Applications

CJC-1295 Without DAC may be investigated in controlled laboratory research involving:

  • GHRH receptor signaling
  • Growth-hormone secretion pathways
  • Endocrine regulation
  • Peptide–receptor interaction studies
  • Growth-hormone and IGF-related research
  • Pharmacokinetic and pharmacodynamic studies
  • Peptide structure–activity relationship research
  • Stability and degradation studies
  • Analytical peptide characterization

Research Advantages

GHRH Pathway Research

Provides a defined experimental peptide for investigating GHRH-mediated growth-hormone signaling.

Non-DAC Formulation

The absence of the DAC modification makes it useful for comparative studies examining differences between shorter-acting and prolonged-acting GHRH analogues.

Comparative Peptide Research

Can be compared with native GHRH, CJC-1295 with DAC, and other GHRH analogues to investigate receptor activity and pharmacological behavior.

Analytical Utility

Suitable for laboratory characterization involving peptide identity, purity, molecular mass, concentration, stability, and degradation products.

Potential Research Areas

Research may include:

  • Growth-hormone physiology
  • GHRH receptor biology
  • Endocrine signaling
  • Peptide pharmacology
  • GH/IGF-axis research
  • Receptor-binding studies
  • Structure–activity relationship investigations
  • Pharmacokinetic studies
  • Peptide stability research
  • Analytical characterization

Product Specifications

Specification Details
Product Name CJC-1295 Without DAC
Type Synthetic GHRH analogue
Primary Research Target GHRH receptor pathway
Category Experimental research peptide
Form Peptide formulation
Research Areas Endocrine & peptide pharmacology
Intended Application Laboratory & analytical research
Documentation Batch-specific COA recommended

Quality & Documentation

For legitimate research applications, batch-specific documentation should ideally include:

  • Peptide identity
  • Sequence/structural confirmation
  • Purity or assay
  • Molecular-weight confirmation
  • Peptide content
  • Batch or lot number
  • Certificate of Analysis (COA)
  • Stability information
  • Relevant analytical testing results

Because “CJC-1295 Without DAC” can be described differently by commercial suppliers, exact peptide identity and sequence should be confirmed through manufacturer documentation and analytical testing before making detailed composition claims.

Important Disclaimer

CJC-1295 Without DAC is an experimental peptide and is not an approved general therapeutic product. It is not intended for human or veterinary consumption, diagnosis, treatment, prevention, or mitigation of disease.

Research involving CJC-1295 should not be marketed as proof of human benefits such as increased muscle mass, anti-aging effects, fat loss, or improved athletic performance. Findings from experimental studies should not be substituted for established clinical evidence.

This description is provided for scientific, product-identification, and legitimate laboratory research purposes only and does not provide dosing or administration instructions.